Evidence map›Paper›PMID 41268339›Full record

ArticleBioactive materials2025

A naturally derived lipopeptide lipid nanoparticle platform enabling multiple nucleic acids delivery.

Han Xiao, Bailin Feng, Dongdong Gao, Shuangni Shi, Yiqing Yang, Yiwei Zhang, Fengyang Wang, Qi Yao, Haiqing Song, Ying Liu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Design of Lipopeptides and dsRNA-Lipopeptide Complexes for Sprayable RNAi-Based Plant Protection.Journal of peptide science : an official publication of the European Peptide Society · 2026
    Article
  2. Bioactive lipid-derived nanoparticles for RNA delivery.Materials today (Kidlington, England) · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Han XiaoCollege of Materials Science and Engineering, Zhejiang University, Hangzhou, Zhejiang, 310058, China.
Bailin FengDepartment of Chemical Engineering, University of Illinois Chicago, Illinois, 60607, United States.
Dongdong GaoSchool of Engineering, Westlake University, Hangzhou, Zhejiang, 310030, China.
Shuangni ShiSchool of Engineering, Westlake University, Hangzhou, Zhejiang, 310030, China.
Yiqing YangDepartment of Chemical Engineering, University of Illinois Chicago, Illinois, 60607, United States.
Yiwei ZhangSchool of Engineering, Westlake University, Hangzhou, Zhejiang, 310030, China.
Fengyang WangSchool of Engineering, Westlake University, Hangzhou, Zhejiang, 310030, China.
Qi YaoDepartment of Joint Surgery, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
Haiqing SongSchool of Engineering, Westlake University, Hangzhou, Zhejiang, 310030, China.
Ying LiuDepartment of Chemical Engineering, University of Illinois Chicago, Illinois, 60607, United States.
Gang ChengSchool of Engineering, Westlake University, Hangzhou, Zhejiang, 310030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) have emerged as versatile platforms for nucleic acid-based therapies. Despite advancements, key challenges remain in achieving tissue-specific delivery while maintaining low toxicity and tunable properties essential for therapeutic applications. Here, we report a novel high-performance LNP platform employing arginine-histidine peptide-dioleoylphosphatidylethanolamine (RmHnC-DOPE) lipopeptides as core components. Through systematic optimization of arginine-to-histidine ratios, we engineered three variants, R3H7C-DOPE, R4H6C-DOPE, and R5H5C-DOPE, enabling payload-specific and tissue-selective delivery of siRNA, mRNA, and plasmid DNA.

Indexed as

ArginineCationic peptideGene therapyHistidineHypercholesterolemiaIonizable peptideLipid nanoparticleLipopeptide

Identifiers

PMID41268339
PMCPMC12628137

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.